News | March 20, 2024
AstraZeneca buys biopharmaceutical company Fusion
To accelerate the development of next-generation radioconjugates to treat cancer
To accelerate the development of next-generation radioconjugates to treat cancer
Development services for gene and cell therapies is planned to begin first in 2025
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
The agreement extends the customer's suite of cloud DevOps, data engineering, and data platform management solutions
New mass spectrometry instrument and consumables launch during IMSC 2022
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Avacc 3 has significant advantages over existing whooping cough vaccines
Subscribe To Our Newsletter & Stay Updated
